Search
for
Sort by
Research 211–240 of 526
- Effect of Topical Gel Administration of Secretome Hypoxia Mesenchymal Stem Cells (SH-MSCs) on IL-10 and TNF- α Gene Expression (In Vivo Experimental Study in Male Rats of Wistar Strains Model of Fluconazole-Induced Alopecia)
- A consensus-based treatment algorithm for alopecia areata in adolescents and adults: integrating severity, quality of life, and disease dynamics
- Elevation of circulating DNAs of disease-associated cytokines in serum cell-free DNA from patients with alopecia areata
- An updated review of the sebaceous gland and its role in health and diseases Part 2: Pathophysiological clinical disorders of sebaceous glands
- An Open-Label Pilot Study to Evaluate the Efficacy of Tofacitinib in Moderate to Severe Patch-Type Alopecia Areata, Totalis, and Universalis
- The Changing Landscape of Alopecia Areata: The Therapeutic Paradigm
- Efficacy of tofacitinib in treatment of alopecia universalis in two patients
- Experience with oral tofacitinib in two adolescents and seven adults with alopecia areata
- Novel therapies for alopecia areata: The era of rational drug development
- Evolution of Ritlecitinib Population Pharmacokinetic Models During Clinical Drug Development
- Etiopathogenesis of Alopecia Areata
- Clinical Perspectives on Alopecia: From Hair Follicle Biology to Advanced Therapies
- 290 Brepocitinib improves cicatricial alopecia and downregulates key T-helper biomarkers
- Association of JAK 1 and JAK 2 gene polymorphism with alopecia areata risk: a case–control genetic study
- Case Report: Successful Treatment of Alopecia Universalis With Tofacitinib and Increased Cytokine Levels: Normal Therapeutic Reaction or Danger Signal?
- Interleukin-15 and Tumor Necrosis Factor-α in Iraqi Patients with Alopecia Areata
- Review of Promising Off-Label Use of Deucravacitinib
- A review of Janus kinase inhibitor use in scarring alopecia
- Exploring the efficacy of baricitinib in treating alopecia areata after failed Janus kinase inhibitor therapy
- Short-term Efficacy of Tofacitinib, a JAK Inhibitor, in IFIH1-related Aicardi-Goutières Syndrome
- LB1034 Meta-analysis of scalp transcriptome defines alopecia areata subtypes and molecular response to four (4) treatments with jak inhibiting properties
- A Patient Preference-Weighted Quantitative Benefit-Risk Analysis of Ritlecitinib for Alopecia Areata to Inform Medical Decision Making
- Hair regrowth in a patient with alopecia universalis and psoriasis vulgaris during deucravacitinib therapy
- Application of Baricitinib in Dermatology
- Janus kinase inhibitors for alopecia areata: A narrative review
- Hair follicle targeting via gelatin coated transferosomes loaded with tofacitinib citrate for enhanced treatment of alopecia areata: Clinical evaluation of alopecia areata patients
- Effects of Natural Herbal Marker Compounds on Human Dermal Papilla Cell Growth Regulation
- JAK Inhibitors for Treatment of Alopecia Areata
- JAK inhibition in the treatment of alopecia areata – a promising new dawn?
- Long‐term safety and efficacy of ritlecitinib in adults and adolescents with alopecia areata and at least 25% scalp hair loss: Results from the ALLEGRO‐LT phase 3, open‐label study